Breye Therapeutics is a clinical stage biopharmaceutical company headquartered in Denmark pursuing a mission to develop novel oral therapies for the treatment of retinal vascular diseases. The Company is developing de-risked, safe and novel small molecules suited for oral administration which have a strong scientific rationale for treating diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). Breye raised a seed round from Novo Holdings and Sound BioVentures and received financial support from the BioInnovation Institute, the Danish Growth Foundation (Vækstfonden) and the Danish Innovation Foundation (Innovationsfonden).
